{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-038859","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.034709+00:00","generated_at":"2026-05-15T07:48:04.448036+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CytoSorbents receives Nasdaq extension to Sept 28, 2026 for minimum bid price compliance","bullets":["Received 180-day extension until Sept 28, 2026 to regain $1.00 minimum bid price compliance.","Previously failed to meet compliance by March 31, 2026; had been notified in October 2025.","Company considering options including reverse stock split to regain compliance.","No assurance of regaining compliance; delisting risk remains.","No immediate effect on listing or SEC reporting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-038859","json":"https://secwatch.observer/filing/0001104659-26-038859.json","markdown":"https://secwatch.observer/filing/0001104659-26-038859.md","text":"https://secwatch.observer/filing/0001104659-26-038859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/tm2611004d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:48:04.448036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cccde76915b976920347c3e85e816d7a314e5111","claim":"Cytosorbents Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware corporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension, or until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with Nasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001213900-26-063575","ticker":"ISPC","company_name":"iSpecimen Inc.","filed_at":"2026-06-01T21:00:15+00:00","headline":"iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063575","json":"https://secwatch.observer/filing/0001213900-26-063575.json","markdown":"https://secwatch.observer/filing/0001213900-26-063575.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/ea0292875-8k_ispecimen.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 29, 2026, iSpecimen Inc. (the “Company”)\nreceived a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)\nnotifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum\nof $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report\non Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May\n29, 2026, the Company doe","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1558569/000121390026063575/0001213900-26-063575-index.htm"}},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm"}},{"accession":"0001493152-26-026442","ticker":"HWH","company_name":"HWH International Inc.","filed_at":"2026-05-29T21:21:49+00:00","headline":"HWH International receives Nasdaq deficiency notice for equity below $2.5M threshold","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026442","json":"https://secwatch.observer/filing/0001493152-26-026442.json","markdown":"https://secwatch.observer/filing/0001493152-26-026442.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/0001493152-26-026442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 29, 2026 HWH International Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’\nequity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) because the Company’s stockholders’\nequity of $2,078,220 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 was below the\nrequired minimum of $2.5 million, and because, as of May 29, 2026, the Company did","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226026442/0001493152-26-026442-index.htm"}},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001683168-26-004399","ticker":"CSAI","company_name":"CLOUDASTRUCTURE, INC.","filed_at":"2026-05-29T21:09:11+00:00","headline":"Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004399","json":"https://secwatch.observer/filing/0001683168-26-004399.json","markdown":"https://secwatch.observer/filing/0001683168-26-004399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/cloud_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 26, 2026, Cloudastructure,\nInc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq\nStock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for\nthe period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which\nrequires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional\ntime to review and confirm the accounting treatment for its outstand","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1709628/000168316826004399/0001683168-26-004399-index.htm"}},{"accession":"0001493152-26-026412","ticker":"CETY","company_name":"Clean Energy Technologies, Inc.","filed_at":"2026-05-29T20:57:27+00:00","headline":"Clean Energy Technologies receives Nasdaq delisting notice for late Q1 filing","event_type":"regulatory","sec_items":["3.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026412","json":"https://secwatch.observer/filing/0001493152-26-026412.json","markdown":"https://secwatch.observer/filing/0001493152-26-026412.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1329606/000149315226026412/0001493152-26-026412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1329606/000149315226026412/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 26, 2026, Clean Energy Technologies, Inc. (the “ Company ”) received a written notice (the “ Notice ”)\nfrom the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not\nin compliance with Nasdaq Listing Rule 5250(c)(1) (the “ Rule ”) because the Company had not yet filed its Quarterly\nReport on Form 10-Q for the period ended March 31, 2026 (the “ Quarterly Report ”). The\nRule requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. The Notice has\nno immediate effect on the listing","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1329606/000149315226026412/0001493152-26-026412-index.htm"}},{"accession":"0001193805-26-000723","ticker":"GURE","company_name":"GULF RESOURCES, INC.","filed_at":"2026-05-29T20:45:30+00:00","headline":"Gulf Resources receives Nasdaq delisting notice for late Q1 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000723","json":"https://secwatch.observer/filing/0001193805-26-000723.json","markdown":"https://secwatch.observer/filing/0001193805-26-000723.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/e665526_8k-gulfresources.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 26, 2026, Gulf Resources\n(the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq\nStock Market LLC (“Nasdaq”), indicating that, as a result of not having timely filed its quarterly report on Form 10-Q for\nthe quarter ended March 31, 2026 (the “Form 10-Q”), and the Company remains delinquent in filing its annual report on Form\n10-K for the year ended December 31, 2025 (the “Initial Delinquent Filing”), the Company is in non-compliance with Nasdaq\nListing Rule 5250(c)(1), which requires timely filing all required periodic financial reports wit","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/885462/000119380526000723/0001193805-26-000723-index.htm"}},{"accession":"0001628280-26-039190","ticker":"FTHM","company_name":"Fathom Holdings Inc.","filed_at":"2026-05-29T20:15:13+00:00","headline":"Fathom Holdings receives Nasdaq notice for late Q1 2026 10-Q filing; 60 days to submit plan","event_type":"regulatory","sec_items":["3.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039190","json":"https://secwatch.observer/filing/0001628280-26-039190.json","markdown":"https://secwatch.observer/filing/0001628280-26-039190.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/0001628280-26-039190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/fthm-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"April 1, 2026, CytoSorbents Corporation, a Delaware\ncorporation (the “Company”), received a letter (the “Extension Notice”) from the Listing Qualifications Staff\n(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising that the Company has been granted a 180-day extension,\nor until September 28, 2026, to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued\nlisting on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), in accordance with\nNasdaq Listing Rule 5810(c)(3)(A). If at any time prior to","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926038859/0001104659-26-038859-index.htm","comparable_excerpt":"May 22, 2026, Fathom Holdings Inc. (the “Company”) received a notification letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the “Filing Requirement”). In accordance with Nasdaq’s listing rules, the Company has 60 calendar days from the date of the notification letter","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1753162/000162828026039190/0001628280-26-039190-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}